Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Abeona Therapeutics (ABEO)

Abeona Therapeutics (ABEO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 271,553
  • Shares Outstanding, K 57,049
  • Annual Sales, $ 5,820 K
  • Annual Income, $ 71,180 K
  • EBIT $ -89 M
  • EBITDA $ -86 M
  • 60-Month Beta 1.22
  • Price/Sales 47.25
  • Price/Cash Flow N/A
  • Price/Book 1.64

Options Overview Details

View History
  • Implied Volatility 244.76% (+122.96%)
  • Historical Volatility 44.60%
  • IV Percentile 71%
  • IV Rank 16.81%
  • IV High 1,170.59% on 01/14/26
  • IV Low 57.72% on 08/19/25
  • Expected Move (DTE 10) 0.13 (2.65%)
  • Put/Call Vol Ratio 6.12
  • Today's Volume 1,758
  • Volume Avg (30-Day) 2,912
  • Put/Call OI Ratio 0.27
  • Today's Open Interest 26,397
  • Open Int (30-Day) 37,395
  • Expected Range 4.68 to 4.94

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.34
  • Number of Estimates 3
  • High Estimate $-0.32
  • Low Estimate $-0.38
  • Prior Year $-0.24
  • Growth Rate Est. (year over year) -41.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.23 +13.71%
on 03/30/26
5.32 -9.59%
on 03/10/26
-0.04 (-0.82%)
since 03/06/26
3-Month
4.23 +13.71%
on 03/30/26
5.68 -15.39%
on 01/16/26
-0.41 (-7.85%)
since 01/07/26
52-Week
3.93 +22.39%
on 04/09/25
7.54 -36.21%
on 08/15/25
+0.30 (+6.77%)
since 04/07/25

Most Recent Stories

More News
Abeona Therapeutics® Announces Appointment of Keith A. Goldan to its Board of Directors

CLEVELAND, April 07, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the appointment of Keith A. Goldan as a new independent member to its Board of Directors, effective...

ABEO : 4.81 (+1.05%)
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CLEVELAND, April 06, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards...

ABEO : 4.81 (+1.05%)
Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in New York

CLEVELAND, April 02, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced activation of NewYork-Presbyterian/Columbia University Irving Medical Center in New York, NY as the...

ABEO : 4.81 (+1.05%)
Abeona Therapeutics: Q4 Earnings Snapshot

Abeona Therapeutics: Q4 Earnings Snapshot

ABEO : 4.81 (+1.05%)
Abeona Therapeutics® Reports Full Year 2025 Financial Results and Corporate Updates

- First ZEVASKYN ® commercial patient treatment completed in December - - ZEVASKYN launch momentum building in first quarter 2026 – - $191.4M in cash, cash equivalents and short-term...

ABEO : 4.81 (+1.05%)
Abeona Therapeutics® Provides Business Update Highlighting Building Momentum in ZEVASKYN® Commercial Launch

CLEVELAND, March 09, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced an update on the building momentum in the Company’s launch of FDA-approved ZEVASKYN (prademagene...

ABEO : 4.81 (+1.05%)
Abeona Therapeutics® Announces Date of Fourth Quarter / Full Year 2025 Financial Results and Participation in Upcoming 2026 Leerink Global Healthcare Conference

CLEVELAND, March 03, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it will host a conference call on Tuesday, March 17, 2026 at 8:30 a.m. ET to discuss its fourth quarter...

ABEO : 4.81 (+1.05%)
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CLEVELAND, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards...

ABEO : 4.81 (+1.05%)
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CLEVELAND, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new executive and non-executive employees who joined the Company....

ABEO : 4.81 (+1.05%)
Abeona Therapeutics® Announces Appointment of Mohamad Tabrizi as Chief Business Officer

CLEVELAND, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the appointment of Mohamad Tabrizi, M.S., M.B.A., as Senior Vice President, Chief Business Officer...

ABEO : 4.81 (+1.05%)

Business Summary

Abeona Therapeutics, Inc. is engaged in developing and delivering gene therapy and plasma-based products for rare diseases. Abeona Therapeutics Inc., formerly known as PlasmaTech Biopharmaceuticals, Inc., is based in Dallas, United States.

See More

Key Turning Points

3rd Resistance Point 5.16
2nd Resistance Point 5.01
1st Resistance Point 4.91
Last Price 4.81
1st Support Level 4.66
2nd Support Level 4.51
3rd Support Level 4.41

See More

52-Week High 7.54
Fibonacci 61.8% 6.16
Fibonacci 50% 5.74
Fibonacci 38.2% 5.31
Last Price 4.81
52-Week Low 3.93

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.